市場調查報告書
商品編碼
1272857
乳癌市場 - 三陰性-KOL的洞察Breast Cancer - Triple Negative - KOL Insight |
本報告提供三陰性乳癌市場相關調查,現在及未來的治療流程,已上市及開發平台的治療藥趨勢等彙整資訊。
What's exciting oncologists in triple-negative cancer therapy? What clinical benefits do KOLs cite for AstraZeneca/Daiichi Sankyo's pipeline datopotamab deruxtecan and why will the readouts of the BEGONIA trial be significant? Why do experts believe the mechanism of action of G1 Therapeutics' late-stage CDK4/CDK6 inhibitor Cosela could lead to improved outcomes? KOLs critically assess the prospects of launched and pipeline therapies.
In addition to the full report, licensed users have access to the Report Highlights slidedeck and KOL Bulletins via the attachments area.